Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >
Knockdown of legumain inhibits cleavage of annexin A2 in the mouse kidney
Title: | Knockdown of legumain inhibits cleavage of annexin A2 in the mouse kidney |
Authors: | Yamane, Takuya Browse this author | Hachisu, Rei Browse this author | Yuguchi, Motoki Browse this author | Takeuchi, Keisuke Browse this author | Murao, Sato Browse this author | Yamamoto, Yoshio Browse this author | Ogita, Hisakazu Browse this author | Takasawa, Toshihide Browse this author | Ohkubo, Iwao Browse this author | Ariga, Hiroyoshi Browse this author →KAKEN DB |
Keywords: | Legumain | Annexin A2 | Cationic liposome | siRNA | In vivo | Mouse kidney |
Issue Date: | 11-Jan-2013 |
Publisher: | ACADEMIC PRESS INC ELSEVIER SCIENCE |
Journal Title: | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS |
Volume: | 430 |
Issue: | 2 |
Start Page: | 482 |
End Page: | 487 |
Publisher DOI: | 10.1016/j.bbrc.2012.12.010 |
PMID: | 23237799 |
Abstract: | Legumain (EC 3.4.22.34) is an asparaginyl endopeptidase. Strong legumain activity was observed in the mouse kidney, and legumain was highly expressed in tumors. We previously reported that bovine kidney annexin A2 was co-purified with legumain and that legumain cleaved the N-terminal region of annexin A2 at an Asn residue in vitro. In this study, to determine whether annexin A2 is cleaved by legumain in vivo, siRNA-lipoplex targeting mouse legumain was injected into mouse tail veins. Mouse kidneys were then isolated and the effect of knockdown of legumain expression on annexin A2 cleavage was examined. The results showed that both legumain mRNA and protein expression levels were decreased in the siRNA-treated mouse kidneys and that legumain activity toward a synthetic substrate, Z-Ala-Ala-Asn-MCA, was decreased by about 40% in the kidney but not in the liver or spleen. Furthermore, cleavage of annexin A2 at the N-terminal region was decreased in the mouse kidney that had been treated with the legumain siRNA-lipoplex. These results suggest that legumain siRNA was delivered to the kidney by using LipoTrust and that the reduced legumain expression inhibited legumain-induced degradation of annexin A2 in vivo. (C) 2012 Elsevier Inc. All rights reserved. |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/52625 |
Appears in Collections: | 薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 山根 拓也
|